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Abstract
Background: The rapid expansion of methadone maintenance treatment (MMT) services has significantly improved
health status and quality of life of patients. However, little is known about its impacts on addiction-related stigma
and associated factors.
Methods: A cross-sectional survey was conducted in 2013 in Vietnam’s capital, Hanoi, and Nam Dinh province
among 1016 methadone maintenance patients; 26.6 % at provincial AIDS centers (PAC) and 73.4 % at district health
centers (DHC), respectively. Drug addiction history and related stigma, health status, MMT-related covariates, and
sociodemographic characteristics were interviewed.
Results: More than one-sixth of the sample reported experiencing felt or enacted stigma, including Blame or
Judgement (17.2 %), Shame (19.9 %), or Others’ fear of HIV transmission (17.1 %). These proportions were higher in
PACs than in DHCs, which are integrated with other HIV or general health care services. Very few patients reported
being discriminated at the workplace (2.5 %) or at health care services (1.7 %); however, 15.6 % of patients at
PACs and 10.6 % of patients at DHCs reported discrimination in their communities. Drug users taking MMT for
longer periods were less likely to report felt stigma. Other factors associated with stigma against MMT patients
included the lack of comprehensive services, higher education, presence of pain/discomfort, and anxiety/
depression, self-reported HIV positive, and number of previous drug rehabilitation episodes.
Conclusion: The study shows a high level of stigma against MMT patients and emphasizes the necessity to
integrate MMT with comprehensive health and support services. Mass communication campaigns to reduce
stigma against people with drug addiction and HIV/AIDS, as well as vocational trainings and jobs referrals for
MMT patients, are needed to maximize the benefits of MMT programs in Vietnam.
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Background
Illicit drug use has been recognized as a major global pub-
lic health issue and continues to drive HIV epidemics in
various low and middle-income countries. In 2013, an es-
timation of 213 million people still used illicit drugs, with
27 million having health problems and approximately 1.65
million living with HIV making it one of the leading at-
tributable factors to the global burden of disease [1]. In
Vietnam, along with sex workers, people who inject drugs
(PWID) have been labelled “social evils” due to their high
prevalence of perceived immoral behaviors such as crim-
inal activities or deteriorating health, which could threaten
the safety of the population [2, 3].
Methadone is a highly effective medication for opioid
dependence [4] and methadone maintenance treatment
(MMT) has been found to improve health status and
promote access to health care among drug users [5–7].
Moreover, MMT helps to reduce the frequency of illicit
drug use [7–9], HIV-related risk behaviors [10, 11] and
illegal activities [12, 13]. Expanding the coverage of
MMT has a major role as a cost-effective strategy in
planning HIV/AIDS prevention and control programs in
both lower and upper-income countries [7, 14, 15].
However, drug users might confront stigmatization
even when they enroll in MMT programs [14]. Those in-
fected with HIV/AIDS may suffer from drug use and
HIV stigma. Discrimination may occur at multiple loca-
tions, such as health care facilities and family, commu-
nity, or work places. For example, a study of Ahern et al.
showed that 75.2 % of drug users experienced discrimin-
ation in their family [16]. Stigma attached to drug use
has been found to have negative effects on the health
status of drug users and to hinder treatment adherence
and health improvement [14, 17, 18]. Therefore, under-
standing influential factors and identifying strategies to
reduce drug addiction-related stigma are essential for
maximizing the effectiveness of MMT programs.
In Vietnam, PWID are one of the most-at-risk popula-
tions and account for about a half of the total number of
people living with HIV/AIDS [6]. To respond, the
government of Vietnam has developed comprehensive
HIV/AIDS policies and programs, including a plan for
expanding MMT programs to 80,000 drug users [19]. In
2015, there were only 170 MMT clinics nationwide with
31,200 patients [20, 21]. MMT service has been delivered
in stand-alone or integrative models, which are co-
located or managed with other HIV-related or general
health care services. The MMT services are organized
with trained specialists and standardized facilities follow-
ing national guidelines established by the Vietnam
Ministry of Health. There have been studies that exam-
ined the experiences of MMT patients and sources of
stigma [14, 22–24] as well as the role of services pro-
viders. Very few studies, however, have focused on differ-
ent service delivery models or have been conducted in
the context of a large drug injection-related HIV epi-
demic. This study examines the differences in levels of
felt and enacted stigma that MMT patients may experi-
ence across different service delivery models and levels
of health administration.
Methods
Survey design and sampling
A cross-sectional survey was performed from June to
August 2013 in Hanoi and Nam Dinh provinces. There
were five MMT clinics involved, four of which were lo-
cated at district health centres (DHC), namely Tu Liem,
Ha Dong, Long Bien, and Xuan Truong, and one clinic
was at Nam Dinh Provincial AIDS Center (PAC). The
characteristics of study sites are listed in Table 1. We se-
lected the two provinces in consultation with program
managers at the Vietnam Authority of HIV/AIDS for a
purposive comparison of an experienced setting, Hanoi,
and a new setting, Nam Dinh Province. The MMT sites
were primarily selected for the comparison of various
service delivery models in different level of health ad-
ministration. In general, drug users register at the near-
est MMT clinics and these clinics provide treatment
regardless of patients’ HIV status. In the organization of
Vietnam’s health services delivery system, the regional
polyclinic is providing primary health care for an area
that combines several communes and is linked to com-
mune health stations [25, 26]. Therefore, the criteria for
enrolling drug users in selected MMT were indifferent.
Eligibility criteria for recruiting participants included:
1) taking or initiating MMT in selected sites; 2) present-
ing at clinics during study periods; 3) being 18 years old
or above; 4) having the capacity to answer questionnaire
within 20 min and 5) agreeing to participate. A conveni-
ent sampling technique was used to enroll a total of
Table 1 Study settings and sample size
Level Settings Site Name Type of services Sample size
Province Nam Dinh City Provincial AIDS Center MMT+ VCT 270
District (rural) Xuan Truong District District Health Center MMT+ VCT + ART + GH 151
District (urban) Tu Liem District District Health Center MMT+ VCT + ART + GH 201
District (urban) Long Bien District District Health Center MMT+ VCT + ART + GH 184
District (urban) Ha Dong District Regional Polyclinic MMT+ GH 210
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1016 patients in this study. Patients were invited into a
designated room for face-to-face interviewing. Before
the interview, participants were introduced to the study
and asked to provide written informed consent. The re-
sponse rate was 80–90 % across sites. Interviewers were
master’s students of public health at Hanoi Medical
University. The students were working in HIV study and
had no affiliation with the clinics in which they invited
patients to participate.
Measures and instruments
A structured questionnaire was developed to use in this
study. Data on socioeconomic characteristics, drug use
behaviors, HIV status was interviewed. Drug use infor-
mation included age at initial drug use, time since first
drug injection, times of previous drug rehabilitation,
and duration of MMT treatment. Health status of re-
spondents was measured in five dimensions (mobility,
self-care, usual activities, pain/discomfort, and anxiety/
depression) using the five-level EQ-5D (EQ-5D-5 L) in-
strument that has been validated and widely used in
Vietnamese populations [6, 27, 28]. Responses were
then recorded to the EQ-5D dimensions as either hav-
ing any health problems or no problems.
It has been well-documented that the stigma against
HIV and drug use in Vietnam has been fueled by both the
fear of HIV infection and social values and by judgements
on addiction and other risk behaviours [3, 18, 29–32]. In
some settings that contain large drug-using populations
with generalized HIV epidemics, the stigma and discrim-
ination against HIV/AIDS and addiction are intertwined
[3, 33, 34]. We referred to the Substance Abuse Self-
Stigma Scale by Luoma and measures of HIV-related
stigma [35, 36]. In addition, we adapted the conceptual
framework by Parker and Aggleton to construct the meas-
ure of drug addiction-related stigma among MMT pa-
tients [37]. We then piloted the measures in drug users
and people living with HIV/AIDS. The final measure of
stigma included five dimensions: (1)Blame/Judgement, (2)
Shame, (3) Discrimination in various settings (work place,
health care services, family, and community), (4) Disclos-
ure of addiction or health status (including HIV-positive if
seropositive), and (5) Other’s fear of HIV transmission
among those patients who self-reported being HIV-
positive [36]. Respondents were asked if they had experi-
enced any of the above types of stigma within the last
month. The measure, for example, included the following
questions with the response options: Yes/No/Not answer.
1. In general, have you recently been blamed or
criticized because of your health status and drug use
behaviors?
2. Do you currently feel shame because of your health
status and drug use behaviors?
3. Have you felt discriminated against or treated badly
by others? In which circumstances (work place/all
health facilities/family/community/others)?.
4. Have you ever disclosed your health status and drug
use behaviors with others? With whom did you
share?
5. (For HIV positives) Has anyone expressed fear of
contracting HIV from casual contacts with you?
Statistical analysis
T-test and χ2 tests were used to compare differences of
characteristics among different services models. Multi-
variate logistic regression was employed to determine the
associated factors with self-stigma, discrimination, and
disclosure. In this study, a stepwise backward selection
strategy was applied along with multivariate regression to
have reduced models. This strategy used threshold with
the log-likelihood ratio test to have predictors with
p-values of < 0.1 included.
Ethics, consent and permissions
The protocol of this study was reviewed and approved by
the Vietnam Authority of HIV/AIDS Control's Scientific
Research Committee. Written informed consent was ob-
tained from all participants. Patients could withdraw at
any time without the influence on their current treatment.
Results
In total, 1016 patients participated in this study; 746
were receiving MMT at one of four DHCs, and 270
others were receiving MMT at Nam Dinh PAC. Among
those, 98.7 % were male and the mean age was 36.8 years
(SD = 7.7). The majority lived with a spouse or partner
(67.7 %) and had high school education or below
(93.4 %). The percentage of patients who were currently
working was 74.6 %, and of these, 53.4 % were self-
employed, 9.8 % were workers or farmers, and 11.4 %
had other jobs (white collars, students, and other)
(Table 2).
Table 3 presents health status, history of drug addic-
tion, and MMT utilization of participants. The average
age of drug use initiation was 24.5 years (SD = 6.7), cor-
responding to an average duration of drugs use of
13.3 years (SD = 5.9) and drug injection duration of
10.2 years (SD = 4.9). Enrolled patients experienced ap-
proximately 5 episodes (mean = 4.8) of drug rehabilita-
tion prior to MMT. The duration of MMT utilization
was 16.5 months on average (SD = 11.0); patients from
PAC experienced an average of 11.4 months (SD = 7.2)
while patients from DHC had undergone a longer
duration on MMT (mean = 18.4 months, SD = 11.5). Re-
garding health status of patients, we found homogeneity
in outcomes between provincial and district health facil-
ities, except a higher prevalence of pain or discomfort
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among patients at DHCs. The prevalence of patients
who reported any health problem was highest in the
anxiety/depression dimension (20.7 %), followed by
pain/discomfort (19.2 %).4.8 % of patients reported con-
current drug use during MMT and the percentage of
self-reported positive HIV status was 8.1 %.
In Table 4, the proportion of stigma and discrimination
among MMT patients is shown. More than one-sixth of
the sample population reported experiencing different
types of stigma or discrimination related to their addiction
or health status, including Blame/Judgement (17.2 %),
Shame (19.9 %), or Fear of HIV transmission by others
(17.1 %); these percentages were higher in PAC than in
DHCs. There were very few patients who reported
discrimination at the workplace (2.5 %) or at health care
services (1.7 %); however, 15.6 % patients at PAC and
10.6 % patients at DHCs reported discrimination from
their communities. The proportion of respondents who
disclosed their addiction or health status to others was
low (with spouse (58.3 %), parents (50.4 %), health workers
(37.3 %), and peer educators (14.3 %)). Patients who were
taking MMT at DHCs reported less discrimination and
more disclosure of their status to others.
Table 5 presents the factors that are associated with
stigma and discrimination against drug users. Drug users
taking MMT for longer periods were less likely to report
being blamed or judged (OR = 0.98, 95 % CI = 0.97–0.99),
but they were also less likely to disclose their health condi-
tion to others (OR = 0.96, 95 % CI = 0.95–0.98). A
higher likelihood of disclosing health conditions was asso-
ciated with people living with a spouse (OR = 1.56, 95 %
CI = 1.14–2.15) versus patients living alone. Other factors
that contributed to perceived stigma and discrimination
among MMT patients included higher education,
presence of pain/discomfort and anxiety/depression, self-
reported HIV positive, and number of previous drug
rehabilitation episodes. Moreover, these factors also
increased the likelihood of disclosing addiction and any
health problem among MMT patients.
Discussion
To date, this is the first study comparing drug addiction-
related stigma among MMT patients across different
service delivery models and levels of administration. The
findings showed that though MMT has been known to
improve health behaviors among drug users, a high pro-
portion of users suffered from stigma and discrimination
due to their previous drug addiction or health status. Al-
though felt stigma decreased among patients who were
enrolled in MMT for longer periods and discrimination
was rarely seen in health facilities, workplace, and family
life, felt stigma remained high in communities where pa-
tients live, especially in urban areas and in areas of
higher level of health care service administration.
Stigma in relation to MMT and different service delivery
models
Our findings highlight the encouraging progress in qual-
ity improvement and stigma reduction in HIV-related
health care services in Vietnam. Previously, stigma was
commonly reported in health care services, which re-
duced the access and use of health care and support ser-
vices among people with HIV/AIDS [18], and was
burdensome to health workers in HIV facilities [30]. In
this study, just about 2 % of respondents reported ex-
periencing any discrimination at health care services.
Meanwhile, the high level of discrimination from com-
munities against drug users is consistent with a previous
Table 2 Socioeconomic characteristics of MMT patients by level
of health services administration
Provincial District All p-value
Mean SD Mean SD Mean SD
Age 36.8 7.7 36.8 7.7 36.8 7.6 0.52
N % N % N %
Sex (Male) 266 98.5 737 98.8 1003 98.7 0.73
Educational attainment
Illiterate 4 1.5 13 1.7 17 1.7 0.03
Elementary 21 7.8 98 13.1 119 11.7
Secondary 103 38.2 323 43.3 426 41.9
High 121 44.8 266 35.7 387 38.1
Vocational 12 4.4 20 2.7 32 3.2
University 9 3.3 26 3.5 35 3.4
Marital status
Single 101 37.4 150 20.1 251 24.7 <0.01
Live with
spouse
148 54.8 537 72.0 685 67.4
Live with partner 0 0.0 3 0.4 3 0.3
Divorced 19 7.0 53 7.1 72 7.1




247 91.5 649 87.0 896 88.2 0.17
Buddhism 13 4.8 46 6.2 59 5.8
Catholic 10 3.7 46 6.2 56 5.5
Protestant 0 0.0 5 0.7 5 0.5
Employment
Unemployed 76 28.2 183 24.5 259 25.5 <0.01
Self-employed 159 58.9 383 51.3 542 53.4
White collars 5 1.9 17 2.3 22 2.2
Workers, Farmers 10 3.7 90 12.1 100 9.8
Students 0 0.0 2 0.3 2 0.2
Other jobs 20 7.4 71 9.5 91 9.0
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qualitative analysis in Thai Nguyen Province by Rudolph
et al. [31] In addition to previous studies, we found that
not only socioeconomic status and history of drug re-
habilitation significantly predicted stigma and discrimin-
ation among drug users taking MMT, but also other
major factors included health status and the availability
of comprehensive HIV/AIDS and general health care
services.
In Vietnam, a DHC is the closest health care facility
providing methadone medication for drug dependence
treatment. In this study, patients at DHCs or regional
polyclinics were less likely to be stigmatized compared
to those at PAC. One study by Mukora et al. showed
that patients were concerned about stigma and loss of
privacy if they received treatment in decentralized clinics
[38]. However, a study by Odeny et al. found that decen-
tralized HIV-related services that were integrated into
primary health care did not worsen stigma [39]. The dif-
ferences in patients’ preferences and perceived stigma
highlighted the importance of understanding contextual
factors and stages of the epidemics in each setting. In
this study, fewer patients felt ashamed or experienced
discrimination at MMT clinics with other HIV-related
and general health care services; nonetheless, these re-
sults may not apply to those living in rural areas.
In addition, we found that drug users taking MMT
for longer periods of time felt less blamed or judged
(OR = 0.98, 95 % CI = 0.97–0.99). This may be due to
the effects of MMT on the improvement of health sta-
tus and the reduction of risk behaviors and illegal ac-
tivities, which may promote positive attitudes of family
and others toward MMT patients. Previous studies
have shown that MMT patients improved substantially
Table 3 Health status and history of drug addiction and MMT
Provincial District All p-value
Mean SD Mean SD Mean SD
Age at first drug use 24.3 7.0 24.6 6.7 24.5 6.7 0.10
Time since 1st drug use (yr.) 13.5 5.1 13.2 6.1 13.3 5.9 0.07
Time since 1st drug inject(yr.) 10.9 4.4 9.9 5.1 10.2 4.9 0.12
# previous drug rehabilitation episodes 5.7 7.2 4.5 5.9 4.8 6.3 <0.01
Duration on MMT (month) 11.4 7.2 18.4 11.5 16.5 11.0 <0.01
N % N % N %
Self-reported health problems
Mobility 19 7.04 55 7.37 74 7.28 0.86
Self-care 10 3.7 30 4.02 40 3.94 0.82
Usual Activities 18 6.67 42 5.63 60 5.91 0.54
Pain or Discomfort 37 13.7 143 19.17 180 17.72 0.04
Anxiety or Depression 56 20.74 154 20.64 210 20.67 0.97
Concurrent drug use 15 5.56 34 4.56 49 4.82 0.51
History of drug injection 222 82.22 524 70.24 746 73.43 <0.01
Self-reported HIV status 0 0 0
Negative 239 88.52 637 85.39 876 86.22 0.15
Positive 22 8.15 60 8.04 82 8.07
N/A 9 3.33 49 6.57 58 5.71
Table 4 Proportion of stigma and discrimination among MMT
patients
Provincial District All p-value
N % N % N %
1. Blame, judge 46 19.7 119 16.4 165 17.2 0.25
2. Shame 66 28.5 124 17.2 190 19.9 <0.01
3. Discrimination
Work place 12 4.4 13 1.7 25 2.5 0.01
Health care services 9 3.3 8 1.1 17 1.7 0.01
Family 8 3.0 16 2.1 24 2.4 0.45
Community 42 15.6 79 10.6 121 11.9 0.03
4. Disclosure
Spouse 109 40.4 483 64.8 592 58.3 <0.01
Parents 133 49.3 379 50.8 512 50.4 0.66
Relatives 53 19.6 229 30.7 282 27.8 <0.01
Friends 59 21.9 237 31.8 296 29.1 <0.01
Health workers 72 26.7 307 41.2 379 37.3 <0.01
Peer educators 38 14.1 107 14.3 145 14.3 0.91
5. Others’ fears of HIV 5 22.7 9 15.0 14 17.1 0.41
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in physical health; however, the changes in mental and so-
cial status were moderate and small, respectively [7, 40].
Participants reporting anxiety and depression were also
much more likely to report feeling blamed/judged and
shame. In addition, drug users who currently used drugs
during MMT were more likely to suffer from discrimin-
ation than those who did not. Collectively, these results
indicated the importance of maintaining MMT to reduce
drug use behaviors, as well as the importance of providing
comprehensive mental health care for patients.
The study also suggests that the use of MMT is preferred
more than traditional drug rehabilitation in Vietnam. Less
effective drug rehabilitation was significantly associated
with higher stigma. Drug detoxification is available in
Vietnam [6], but with high episodes of failure rehabilitation,
patients may believe that they cannot be successfully
treated, and therefore, blame themselves for relapsing. In
this study, the proportion of felt stigma was lower than in
other settings. This coincides with findings from previous
studies that MMT helps improve social and economic sta-
tus of patients and their families [5, 7, 40–42].
Notably, the proportion of MMT patients’ felt stigma
in communities was significantly higher than in families,
health facilities, or workplaces. This result suggested that
although participating in MMT program could reduce
stigma in those latter place, stigma remained a great
Table 5 Factors associated with stigma and discrimination against drug users
Blame, judge Shame Discrimination Disclosure of addiction or health status
OR 95 CI OR 95 CI OR 95 CI OR 95 CI
Duration on MMT (months) 0.98a 0.97 0.99 1.00 0.98 1.02 0.99 0.96 1.01 0.96a 0.95 0.98
MMT model (MMT+ PAC - ref)
Rural MMT-ART-VCT-DGH 1.67 0.99 2.82
Urban MMT-ART-VCT-DGH 0.36a 0.22 0.58 0.51a 0.31 0.84 3.21a 2.13 4.83
MMT + Regional poly clinic 0.39a 0.24 0.63
Education (High school or Lower - ref)
College/University 1.82 0.93 3.57 1.96a 1.02 3.74
Marital status
Live with spouse vs. Single 1.56a 1.14 2.15
Religion
Buddhism vs. Cult of ancestors 0.43 0.15 1.22
Employment (Unemployed - ref)
Self-employed 0.72 0.49 1.04
White collars 0.30 0.06 1.44
Workers, Farmers 0.42a 0.19 0.93 0.50a 0.25 0.99 0.52 0.24 1.13 0.49a 0.30 0.80
Other jobs 1.65 0.93 2.95
Self-reported health problems
Mobility 1.82 1.00 3.31 0.39a 0.20 0.74
Self-care 2.12 0.94 4.81
Usual Activities 2.22 0.90 5.47
Pain or Discomfort 2.01a 1.16 3.47
Anxiety or Depression 1.79a 1.19 2.70 2.39a 1.62 3.53 1.49 0.95 2.32 1.66a 1.02 2.69
Self-reported HIV status (Negative - ref)
Positive 1.74a 1.01 3.04
N/A 2.15a 1.04 4.47
# previous drug rehabilitation (None - ref)
1–5 times 2.27 0.88 5.88 0.73 0.49 1.08 1.86a 1.21 2.86
6–10 times 2.89a 1.07 7.80 1.73a 1.03 2.89
> 10 times 2.75 0.85 8.83
Ever inject drug vs. None 1.53 0.94 2.48
Concurrent drug use vs. None 2.44a 1.11 5.37
asignificant at 5 % level
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barrier for MMT patients trying to reenter into their
community. A study conducted by Tomori et al. in
Vietnam showed that even when a person successfully
detoxifies from illicit drugs, they had to confront the
drug-related stigmatization in their community [2].
Therefore, mass media campaigns are necessary to re-
duce stigma against people with HIV/AIDS and history
of drug addiction in settings with large drug injection re-
lated HIV epidemics.
In this study, we also found that patients who were HIV
positive or unknown status were more likely to report
self-stigmatization. Literature suggests that drug users re-
port shameful attitudes and think that HIV might be a
punishment for their past [2]. On the other hand, it is
noteworthy to find that people who were employed were
less likely to feel self-stigmatization. Vocational training
and job referrals should be considered in local planning to
maximize the benefits of MMT programs.
Disclosing MMT patients’ status
Disclosure of status among HIV-positive people and
PWID has been considered a potential method to reduce
the spread of HIV/AIDS. Although the drawbacks of
self-disclosure may include stigma, loss of privacy, and
blame, it may help those high-risk populations to reduce
HIV risk behaviors and increase access to HIV-related
care, as well as being related to better adherence for
those receiving treatment [18]. In present study, patients
receiving MMT at DHC reported a higher percentage of
disclosing their condition to spouses, relatives, health
workers, and friends than patients at PAC. This associ-
ation can be partially explained by the fact that in order
to hide their conditions and avoid discrimination, drug
users tended to receive treatment at a health center far
from their hometowns [43].
People taking MMT in long duration were less likely
to disclose their health status to other people. There
may several reasons be for this finding. First, as we ob-
served, with the improvement in health status due to
long duration of treatment, MMT patients might feel
confident about their health and therefore may think
that they do not need to share their status with other
people. Second, information about MMT patients’ treat-
ment or their past may be used against them at work or
in the community [44].
Most patients shared their status with their spouse
(58.3 %) and parents (50.4 %), who were the closest
relatives of patients. People living with a spouse also
were likely to disclose. Families are a critical source
of financial, physical, and emotional supports, which
facilitate re-entry into the community for drug users
[45]. Therefore, support from family has a central role
in encouraging patients’ disclosure.
Implications
There were several implications that can be drawn from
this study. First, MMT clinics should be integrated with
other health services and decentralized as satellite model
to provide patients with accessible and friendly health
care, which in turn may reduce stigma of patients. Strat-
egies to optimize the effectiveness of this model should
be considered for the scale-up plan of MMT programs.
Second, mass media campaigns in television or on the
internet should be conducted to reduce stigmatization in
the community for MMT patients. Third, the role of par-
ents/spouses should be heightened to help combat diffi-
culties encountered when patients participate in MMT
treatment. Lastly, physical and mental health conditions
of patients should be acknowledged and addressed.
Limitations
Several limitations in this study should be under consider-
ation. First, this cross-sectional design could not establish
causal relation between stigma outcomes and MMT deliv-
ery models. In addition, a qualitative study should be con-
ducted to understand how different models can impact on
the feeling of stigma in accordance to patients’ perceptions
and experiences. Second, Self-report information may be
subject to recall bias. Finally, the convenient sampling
technique limited the generalization of this study.
Conclusions
In conclusion, the study highlighted significant higher
levels of stigma among MMT patients at PAC as com-
pared to people at DHC. The findings suggested the
need to integrate MMT with the satellite model (DHC,
regional poly-clinics, etc.) to reduce stigma. Moreover,
the study emphasized the importance of maintaining
MMT adherence and effectiveness and the importance
of intervening on stigma amongst drug users, family,
health care workers, and community.
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